Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.
Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES, Minnion J, Cuenco J, Ghatei MA, Meeran K, Tan TM, Bloom SR. Cegla J, et al. Among authors: ghatei ma. Diabetes. 2014 Nov;63(11):3711-20. doi: 10.2337/db14-0242. Epub 2014 Jun 17. Diabetes. 2014. PMID: 24939425 Clinical Trial.
Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.
Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR. Tan TM, et al. Among authors: ghatei ma. Diabetes. 2013 Apr;62(4):1131-8. doi: 10.2337/db12-0797. Epub 2012 Dec 17. Diabetes. 2013. PMID: 23248172 Free PMC article. Clinical Trial.
Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.
Tan TM, Salem V, Troke RC, Alsafi A, Field BC, De Silva A, Misra S, Baynes KC, Donaldson M, Minnion J, Ghatei MA, Godsland IF, Bloom SR. Tan TM, et al. Among authors: ghatei ma. J Clin Endocrinol Metab. 2014 Nov;99(11):E2317-24. doi: 10.1210/jc.2014-2143. Epub 2014 Aug 21. J Clin Endocrinol Metab. 2014. PMID: 25144632 Free PMC article.
Oxyntomodulin suppresses appetite and reduces food intake in humans.
Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Cohen MA, et al. Among authors: ghatei ma. J Clin Endocrinol Metab. 2003 Oct;88(10):4696-701. doi: 10.1210/jc.2003-030421. J Clin Endocrinol Metab. 2003. PMID: 14557443 Clinical Trial.
Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR. Neary NM, et al. Among authors: ghatei ma. Endocrinology. 2005 Dec;146(12):5120-7. doi: 10.1210/en.2005-0237. Epub 2005 Sep 8. Endocrinology. 2005. PMID: 16150917 Clinical Trial.
Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging.
Chaudhri OB, Parkinson JR, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA, Ghatei MA, Bloom SR. Chaudhri OB, et al. Among authors: ghatei ma. Biochem Biophys Res Commun. 2006 Nov 17;350(2):298-306. doi: 10.1016/j.bbrc.2006.09.033. Epub 2006 Sep 18. Biochem Biophys Res Commun. 2006. PMID: 17007819
Low-dose pancreatic polypeptide inhibits food intake in man.
Jesudason DR, Monteiro MP, McGowan BM, Neary NM, Park AJ, Philippou E, Small CJ, Frost GS, Ghatei MA, Bloom SR. Jesudason DR, et al. Among authors: ghatei ma. Br J Nutr. 2007 Mar;97(3):426-9. doi: 10.1017/S0007114507336799. Br J Nutr. 2007. PMID: 17313701 Clinical Trial.
522 results